David Fajgenbaum: Once a drug receives FDA approval, its research and development often slows down
“Did you know that once a drug receives FDA approval, its research and development often slows down? It’s a common misconception that approval marks the peak of a drug’s journey. In reality, it’s the opposite. When the drug eventually turns generic, it’s now more affordable and accessible than ever. Yet paradoxically, this is when research and development typically comes to a standstill.
As someone whose life was saved by an old, generic drug, I am deeply invested in this topic. We should be maximising these opportunities, not diminishing them. At Every Cure, we are on a mission to shift the narrative and focus on how we can leverage these accessible drugs to their fullest potential.
What are your thoughts on how we can reinvigorate research and development for generic drugs to enhance their impact and accessibility?”
For the video, click here.
Source: David Fajgenbaum/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023